Journal of Clinical Lipidology 2014-01-01

Fenofibrate causes elevation of betaine excretion but not excretion of other osmolytes by healthy adults.

Michael Lever, Christopher J McEntyre, Peter M George, Sandy Slow, Stephen T Chambers, Christelle Foucher

Index: J. Clin. Lipidol. 8(4) , 433-40, (2014)

Full Text: HTML

Abstract

Cross-sectional data suggest that bezafibrate increases betaine excretion in dyslipidemic patients.We aimed to demonstrate that fenofibrate induces increased betaine excretion in normal subjects and explore whether other 1-carbon metabolites and osmolytes are similarly affected.Urine was collected from 26 healthy adults before and after treatment with fenofibrate (145 mg/day for 6 weeks). Excretions of betaine, N,N-dimethylglycine, free choline, myo-inositol, taurine, trimethylamine-N-oxide, carnitine, and acetylcarnitine were measured by liquid chromatography with mass spectrometric detection.Fenofibrate increased the median betaine excretion from 7.5 to 25.8 mmol/mole creatinine (median increase 3-fold), P < .001. The median increase in N,N-dimethylglycine excretion was 2-fold (P < .001). Median choline excretion increased 12% (significant, P = .029). Participants with higher initial excretions tended to have larger increases (P < .001 in all 3 cases). Fenofibrate did not significantly change the median excretions of myo-inositol, taurine, trimethylamine-N-oxide, and carnitine. The excretion of acetylcarnitine decreased 4-fold on treatment, with no correlation between the baseline and after-treatment excretions. Changes in all urine components tested, except trimethylamine-N-oxide, positively correlated with changes in betaine excretion even when the median excretions before and after were not significantly different.Fibrates increase betaine, and to a lesser extent N,N-dimethylglycine and choline, excretion. Other osmolytes are not elevated. Because the increase in betaine excretion depends on the baseline excretion, large increases in excretion in the metabolic syndrome and diabetes (where baseline excretions are high) could be expected. Replacement with betaine supplements may be considered.Copyright © 2014 National Lipid Association. Published by Elsevier Inc. All rights reserved.

Related Compounds

Structure Name/CAS No. Articles
Formic Acid Structure Formic Acid
CAS:64-18-6
Acetonitrile Structure Acetonitrile
CAS:75-05-8
Methanol Structure Methanol
CAS:67-56-1
Formic acid ammonium salt Structure Formic acid ammonium salt
CAS:540-69-2
Taurine Structure Taurine
CAS:107-35-7
DL-Carnitine hydrochloride Structure DL-Carnitine hydrochloride
CAS:461-05-2
Cadmium chloride Structure Cadmium chloride
CAS:10108-64-2
Betaine Hydrochloride Structure Betaine Hydrochloride
CAS:590-46-5
Inositol Structure Inositol
CAS:87-89-8
Trimethylamine oxide Structure Trimethylamine oxide
CAS:1184-78-7